WeDoctor's Medical Large Language Model: Double Champion in Authoritative Benchmarks, Demonstrating the Effectiveness of AI in Healthcare

WeDoctor's Medical Large Language Model: Double Champion in Authoritative Benchmarks, Demonstrating the Effectiveness of AI in HealthcareThe competition among AI large language models is heating up, with authoritative benchmark platforms becoming a crucial battleground for technology companies to showcase their capabilities. Recently, the latest rankings from MedBench and CMB, two leading Chinese medical large language model evaluation platforms, were unveiled

WeDoctor's Medical Large Language Model: Double Champion in Authoritative Benchmarks, Demonstrating the Effectiveness of AI in Healthcare

The competition among AI large language models is heating up, with authoritative benchmark platforms becoming a crucial battleground for technology companies to showcase their capabilities. Recently, the latest rankings from MedBench and CMB, two leading Chinese medical large language model evaluation platforms, were unveiled. WeDoctor Holdings' WeDoctor Medical Large Language Model achieved outstanding results on both platforms, demonstrating its leading position in the AI healthcare field.

MedBench, launched by the Shanghai AI Laboratory and the Shanghai Digital Medicine Innovation Center, leverages the expertise and knowledge base of top medical institutions to create a fair and rigorous evaluation system for Chinese medical large language models. In MedBench's latest self-testing ranking, WeDoctor's Medical Large Language Model topped the list with a total score of 94.7, exhibiting outstanding performance in several evaluation dimensions, including medical knowledge Q&A, medical language generation, complex medical reasoning, medical language understanding, and medical safety and ethics. It's noteworthy that WeDoctor's model has consistently ranked among the top three on the MedBench self-testing leaderboard for the past six months.

CMB (Comprehensive Medical Benchmarking in Chinese), another authoritative medical large language model evaluation platform, is also a significant stage for the competition. Over the past six months, WeDoctor's Medical Large Language Model has also frequently topped the CMB rankings. Winning first place on both MedBench and CMB, two highly respected platforms, fully demonstrates the model's superior technical capabilities and application potential, earning high recognition from industry "judges." This is not only an affirmation of its technical strength but also a recognition of its powerful capabilities in practical applications.

However, the success of WeDoctor's Medical Large Language Model is not solely based on its technical aspects. Its excellent performance in real-world applications is a key factor in its recognition. WeDoctor's model is not confined to the laboratory; it has been widely applied in real medical scenarios, providing tangible benefits to patients.

For example, in the Healthy Community Collaborative (HCC) projects co-constructed with local governments such as Tianjin, four intelligent agentsAI Doctor, AI Pharmacist, AI Health Management, and AI Smart Controldeveloped based on WeDoctor's Medical Large Language Model have been implemented on a large scale, covering pre-diagnosis, diagnosis, and post-diagnosis health management throughout the entire life cycle. The application of these AI agents has significantly improved the efficiency and quality of medical services.

Data shows that as of June 30, 2024, the compliance rate of inappropriate prescription reminders from WeDoctor Holdings' "AI Doctor" reached 99.97%. "AI Health Management" significantly improved the efficiency of health management personnel, increasing the number of individuals managed per health manager from approximately 550 in 2022 to approximately 2,000 in the first half of 2024. More importantly, empowered by WeDoctor's Medical Large Language Model, the target attainment rate of HbA1c for diabetic members under the Tianjin HCC program rose from 17.8% in January 2023 to 44.2% in June 2024; blood pressure target attainment rate increased from 19.5% to 61.5%; and blood lipid target attainment rate rose from 24.8% to 27.9%. These data powerfully demonstrate the significant effectiveness of WeDoctor's Medical Large Language Model in improving patient health outcomes.

WeDoctor Holdings' success in the AI medical field stems from its continuous research and development investment and technological innovation. As an AI healthcare solution provider, WeDoctor Holdings continuously integrates advanced large language model capabilities and relies on publicly available academic resources and multimodal data to continuously enhance its basic analytical capabilities. Simultaneously, WeDoctor Holdings focuses on breakthroughs in self-developed technologies, emphasizing the deep integration of real-world clinical diagnostic and treatment data and clinical decision-making pathways. Through chronic and specialty disease clinical pathway engines, rational drug use engines, tripartite medical linkage risk control engines, health management engines, and expert reviews, the company clinically validates its inference model solutions to ensure evidence-based compliance.

The capabilities of WeDoctor's Medical Large Language Model are ultimately implemented through the four intelligent agents: AI Doctor, AI Pharmacist, AI Smart Control, and AI Health Management, achieving a closed-loop transformation from technical capabilities to commercial value. More importantly, this process forms a data flywheel effect that enhances training and self-reinforcement, continuously optimizing AI healthcare capabilities through feedback from efficacy and economic evaluations, ultimately achieving improved quality and efficiency.

WeDoctor Holdings' deep cultivation of the AI medical field is not a matter of a single day's effort. As early as 2017, WeDoctor collaborated with Zhejiang University to establish the Ruiyi Artificial Intelligence Research Center, dedicated to promoting the research and application of artificial intelligence technology in the medical and health field. Today, WeDoctor Holdings has scaled up the application of Ruiyi's research results in scenarios such as digital HCCs, achieving significant results.

Currently, four algorithms from WeDoctor HoldingsWeDoctor Medical Large Language Model Algorithm, WeDoctor Medical Assistant Large Language Model Algorithm, WeDoctor Health Assistant Model Algorithm, and WeDoctor Text Generation Algorithmhave been approved by the Cyberspace Administration of China, further demonstrating the company's leading position and technical strength in the AI medical field.

In summary, WeDoctor's Medical Large Language Model's double victory on the MedBench and CMB authoritative platforms, along with its outstanding performance in practical applications, fully demonstrates WeDoctor Holdings' exceptional strength and leading position in the AI healthcare field. WeDoctor Holdings has not only achieved breakthroughs in technology research and development but, more importantly, has successfully translated advanced technology into commercial value, ultimately benefiting a large number of patients and setting a benchmark for the development of Chinese AI healthcare. As a pioneer in Chinese AI healthcare, WeDoctor Holdings' future development is worth anticipating. Its continuous innovation and investment in AI healthcare will surely bring a brighter future for China's healthcare industry. The success of WeDoctor's Medical Large Language Model also provides valuable experience and reference for other AI medical enterprises, driving the entire industry towards a more standardized, regulated, and high-quality direction. In the future, with the continuous advancement of AI technology and the expansion of application scenarios, WeDoctor's Medical Large Language Model will continue to play an important role in providing even better medical services to more patients.

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])